Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting results this Friday before market open. Here’s what you need to ...

AbbVie has scrapped an asset from its ongoing collaboration with Dragonfly Therapeutics, a spokesperson for the Chicago ...

AbbVie on Wednesday said the replicate Phase 3 studies met their co-primary endpoints of reduction in de-pigmentation over the entire body and the face in adults and adolescents with non-segmental ...

AbbVie today announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib (RINVOQ®;15 mg, once daily  in adult and adolescent patients ...

AbbVie (ABBV) announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of ...

AbbVie Inc. is reiterated as a Strong Buy ahead of Q3 earnings, with revenue growth expected to outpace the sector median.

Learn more about whether AbbVie Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Today, Allergan Aesthetics, an AbbVie company, announces their continued partnership with Girls Inc. for the 7th year with programming and funding designed to foster mentorship and ensure girls have ...

With a new approach to creating thymus-targeted medicines for autoimmune diseases, Zag Bio has emerged from stealth with the ...

Baron Health Care Fund gained for the quarter and outperformed its benchmark, the Russell 3000 Health Care Index. Read more ...

The Tax Court’s opinion provides U.S. businesses with greater certainty around tax treatment of major spending decisions, ...

As markets adjust to higher rates and uneven growth, investors are gravitating towards businesses that balance resilience ...